Registry of Lobbyists
| Subject matters | Details | Categories |
|---|---|---|
|
Health
|
As a member company, participation in the Canadian Generic Pharmaceutical Association's legal challenge of the 2006 Amendments to Health Canada's Food and Drug Regulations with respect to the extended period of data exclusivity, as well as further proposed amendments to these regulations.
|
Regulation
|
|
Economic Development, Health, Industry, Science and Technology
|
As part of its renewed biomanufacturing strategy, the Federal Governement has announced its intentions to reinvest in this strategic sector. Sandoz Canada is interested in initiating discussions in this contexte with the potential objective of a joint investment in the life sciences sector.
|
Grant, Contribution or Other Financial Benefit
|
|
Health
|
Health Canada, Innovation, Science & Economic Development Canada and International Trade Canada regarding effective measures to combat counterfeit drugs in Canada and around the world.
|
Policies or Program
|
|
Budget, Health
|
Health Canada regarding Patented Medicine Prices Review Board (PMPRB) Reform and National Pharmacare Program
|
Policies or Program
|
|
Health
|
Health Canada regarding regulation about Requirement for reporting of drug shortages.
|
Regulation
|
|
Economic Development, Health, Industry
|
Health Canada regarding the Cannabis Act (C-45) for medicinal cannabis
|
Legislative Proposal, Bill or Resolution
|
|
Health
|
Health Canada regarding the development and implementation of an approval pathway for Biosimilars as well as pricing policies.
|
Policies or Program
|
|
Health
|
Health Canada regarding the need for appropriate, dedicated resources for the Therapeutic Products Directorate to meet performance targets for the review of generic drug submissions.
|
Policies or Program
|
|
Health, Science and Technology
|
Innovation, Science & Economic Development, with respect to the Patent Act as it pertains to pharmaceuticals.
|
Legislative Proposal, Bill or Resolution
|
|
Health
|
Innovation, Science & Economic Development Canada regarding export provisions of the Patent Act (pharmaceuticals).
|
Legislative Proposal, Bill or Resolution
|
|
Health
|
Innovation, Science & Economic Development Canada regarding the need to restore balance to the Patented Medicines (Notice of Compliance) Regulations with respect to pharmaceuticals and address operational concerns including: lack of finality to proceedings under the Regulations and lack of disincentives to discourage abuse of the Regulations.
|
Regulation
|
|
Health
|
Provide input into Government of Canada's Science and Technology strategy regarding the need for a balanced Intellectual Property regime and the important role competition plays in encouraging innovation.
|
Policies or Program
|
|
Health
|
Provide input into the Government of Canada's negotiations regarding the Canada-European Union Comprehensive Economic and Trade Agreement (CETA) and re-negotiation of NAFTA with respect to pharmaceuticals, counterfeit medicines, border measures and intellectual property.
|
Legislative Proposal, Bill or Resolution
|
| Subject matters | Details | Categories | Added date |
|---|---|---|---|
|
Health
|
Amend Bill C-64 to remove the risks and uncertainty that would undermine the stability and affordability of Canada's drug supply.
|
Legislative Proposal, Bill or Resolution
|
2024-10-08
|
A true leader in its field and trusted partner to hospitals, pharmacies and physicians, Sandoz Canada markets and distributes a wide range of generics, biosimilars and specialty products. Sandoz Canada covers all major therapeutic areas with its broad portfolio of off-patent medicines and works closely with commercial and scientific partners to maximize its collective contribution to society. We offer patient support programs and continuing education, including accredited training programs for healthcare professionals and much more. In addition to the global #1 ranking in biosimilars1 and generic antibiotics2, dermatology3 and transplantation medicines4, Sandoz portfolio of products in Canada includes six biosimilars and over 700 generic products5 covering 250 molecules and medicinal ingredients spanning multiple therapeutic areas.
Michel Robidoux, President & Chief Executive Officer
Address:
110 rue de Lauzon
Boucherville, QC J4B 1E6
Canada
Telephone number:
450-641-4903
Ext.
2598
Fax number:
450-641-8615
Sandoz Canada Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking